| Name | Title | Contact Details |
|---|
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
Invitae is a leader in medical genetic testing, driving genetic information into mainstream medicine to improve healthcare for billions of people. Invitae is aggregating the world`s medical genetic tests into a single service with higher quality, faster turnaround time, and lower prices. By driving down the cost of genetic testing we make it affordable and accessible to everyone who can benefit. Why medical genetics? Within each of us lies information coded in our DNA that can transform our health. Unlocking those answers to make medicine more personalized requires highly specialized, multidisciplinary collaboration. Our platform is setting the standard for the exploding medical genetics industry by harnessing the power of advanced technologies – robotics, artificial intelligence, machine learning, software engineering – and world-class genetic expertise. We provide genetic information that guides decisions for patients facing a vast array of health questions, from ultra-rare diseases and the most common cancers to starting a family. The team driving our mission thrives in a culture designed to enable innovation at scale. We are grounded in freedom with responsibility and a universal sense of urgency and ownership. Employees are empowered to speak up, try new things and make decisions that push us forward. We provide all employees with opportunities to grow and advance, supported by flexible work hours, unlimited paid time off, the ability to work anywhere for many roles and the satisfaction of doing meaningful work. Each day at Invitae means driving forward toward a new era in which everyone can have their health decisions guided by genetics.
San Diego-based Biocept, Inc. (Nasdaq: BIOC) develops and performs diagnostic assays that provide clinically actionable information to improve outcomes for patients with a variety of cancers. Biocept`s unique combination of cell-based and cell-free DNA analysis allows us to rapidly detect and monitor certain cancer biomarkers in blood and cerebrospinal fluid (CSF). Our patented Target Selector™ technology quantitatively analyzes tumor cells for tumor-associated biomarkers, offering high sensitivity and specificity compared with methods currently used by other laboratories. In addition to our broad portfolio of blood-based liquid biopsy tests, we offer the CNSide™ CSF assay, which addresses an unmet clinical need for patients with cancer that has metastasized to the central nervous system. Between 10% and 30% of patients with cancer will develop brain or spinal cord metastasis. Survival is often low, and few are diagnosed early enough for effective therapeutic intervention. CNSide answers three key questions: Is there a tumor? Is there a target for treatment? Is there a trend in treatment response? We offer diagnostic laboratory services for oncologists, pathologists, hospitals, cancer centers, universities, pharmaceutical and clinical researchers, and other healthcare providers. Our CLIA-certified and CAP-accredited laboratory combines a highly trained professional staff with innovative instrumentation for optimal test results and quality control. Biocept works with strategic industry leaders, as well as major cancer centers across the U.S., to further its mission of helping to improve outcomes for cancer patients. We also are utilizing our molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts. Revenue from COVID-19 testing has supported further investment in our core oncology business, positioning the company for long-term success.
VelosBio, Inc. operates as a biotechnology firm specializing in oncology.
BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements.